Found: 11
Select item for more details and to access through your institution.
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 9, p. 1156, doi. 10.1002/ajh.26276
- By:
- Publication type:
- Article
Novel Multiplex Bead-Based Assay for Detection of <i>IDH1</i> and <i>IDH2</i> Mutations in Myeloid Malignancies.
- Published in:
- PLoS ONE, 2013, v. 8, n. 9, p. 1, doi. 10.1371/journal.pone.0076944
- By:
- Publication type:
- Article
Systematic analysis of copper, zinc, and selenium levels in JAK2 V617F-positive myeloproliferative neoplasms.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 6, p. 2177, doi. 10.1007/s00277-024-05624-z
- By:
- Publication type:
- Article
Calreticulin Mutations in Bulgarian MPN Patients.
- Published in:
- Pathology & Oncology Research, 2018, v. 24, n. 1, p. 171, doi. 10.1007/s12253-017-0226-2
- By:
- Publication type:
- Article
Significance of molecular-cytogenetic aberrations for the achievement of first remission in de novo acute myeloid leukemia.
- Published in:
- Turkish Journal of Hematology, 2008, v. 25, n. 4, p. 190
- By:
- Publication type:
- Article
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 11, p. 1170, doi. 10.1002/ajh.24877
- By:
- Publication type:
- Article
Exploration of the role of NKG2D ligands MICA and MICB in JAK2 V617F‐positive myeloproliferative neoplasms.
- Published in:
- HLA: Immune Response Genetics, 2023, v. 102, n. 2, p. 168, doi. 10.1111/tan.15026
- By:
- Publication type:
- Article
Differential modulation of mutant CALR and JAK2 V617F-driven oncogenesis by HLA genotype in myeloproliferative neoplasms.
- Published in:
- Frontiers in Immunology, 2024, p. 01, doi. 10.3389/fimmu.2024.1427810
- By:
- Publication type:
- Article
Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1.
- Published in:
- JAMA: Journal of the American Medical Association, 2015, v. 313, n. 7, p. 695, doi. 10.1001/jama.2015.459
- By:
- Publication type:
- Article
Influence of detection of pretreatment cytogenetic abnormalities on first complete remission and survival in adult acute lymphoblastic leukemia.
- Published in:
- Turkish Journal of Hematology, 2011, v. 28, n. 3, p. 176, doi. 10.5152/tjh.2011.51
- By:
- Publication type:
- Article